The Endocannabinoid System as a Biomarker for Diagnostic and Therapeutic
Applications in Depression and Anxiety

Jocelyne      Alcaraz-Silva; Daniel      Feingold; Gerardo      Viana-Torre; Henning      Budde; Claudio      Imperatori; Sérgio      Machado; Eric      Murillo-Rodríguez
Abstract

Background: Depression and anxiety belong to a family of mental disturbances that have increased significantly in recent years. The etiology of both disorders comprises multiple and complex factors, from genetic background to environmental influence. Since depression and anxiety present severe symptoms, they represent a greater clinical burden and greater therapeutic difficulty. Currently, standardized diagnostic procedures for depression and anxiety allow for the addition of further treatments, including psychotherapy and/or pharmacological intervention, with effective outcomes. However, further steps should be considered with regard to consideration of the endocannabinoid system’s role in depression and anxiety.
Objective: This study aimed to review the evidence from animal research and clinical studies on the role of cannabinoid receptors, the major endocannabinoids -anandamide (AEA) and 2-arachidonoylglycerol (2-AG)- and the enzymes related to the synthesis and degradation of these chemicals as putative biomarkers for diagnostic and therapeutic elements of depression and anxiety.
Methods: This review included the online search, identification, and analysis of articles (basic and clinical trials) published in English in PubMed linked to the role of cannabinoid receptors, AEA, 2- AG, and the enzymes associated with the synthesis and degradation of these endocannabinoids in depression and anxiety.
Results: The neurobiological relevance of the endocannabinoid system offers genetic or pharmacological manipulation of this system as a potential strategy for the diagnostic and clinical management of mood disorders, including depression and anxiety.
Conclusion: Although the described approach in this review is promising, no solid evidence is yet available, and along with additional experiments using animal models that mimic human depression and anxiety, clinical trials are needed to explore the role of the endocannabinoid system’s elements as well as the anandamide membrane transporter, none of which have been adequately studied in depression and anxiety.
Keywords: 2-Arachidonoylglycerol, anandamide membrane transporter, cannabinoid receptors, depression, diacylglycerol lipase, fatty acid amide hydrolase, monoacylglycerol lipase.
[1]
Abate KH, Abebe Z, Abil OZ, et al. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet  2018; 392(10159): 1789-858.
 [http://dx.doi.org/10.1016/S0140-6736(18)32279-7] [PMID: 30496104]

[2]
Richter D, Wall A, Bruen A, Whittington R. Is the global prevalence rate of adult mental illness increasing? Systematic review and meta-analysis. Acta Psychiatr Scand  2019; 140(5): 393-407.
 [http://dx.doi.org/10.1111/acps.13083] [PMID: 31393996]

[3]
Steel Z, Marnane C, Iranpour C, et al. The global prevalence of common mental disorders: A systematic review and meta-analysis 1980-2013. Int J Epidemiol  2014; 43(2): 476-93.
 [http://dx.doi.org/10.1093/ije/dyu038] [PMID: 24648481]

[4]
Schürmann J, Margraf J. Age of anxiety and depression revisited: A meta-analysis of two European community samples (1964-2015). Int J Clin Psychol  2018; 18(2): 102-12.
 [http://dx.doi.org/10.1016/j.ijchp.2018.02.002] [PMID: 30487915]

[5]
Fusar-Poli P, Davies C, Solmi M, et al. Preventive treatments for psychosis: Umbrella review (just the evidence). Front Psychiatry  2019; 10: 764.
 [http://dx.doi.org/10.3389/fpsyt.2019.00764] [PMID: 31920732]

[6]
Brown JVE, Walton N, Meader N, et al. Pharmacy-based management for depression in adults. Cochrane Database Syst Rev  2019; 12: CD013299.
 [http://dx.doi.org/10.1002/14651858.CD013299.pub2] [PMID: 31868236]

[7]
Chen P. Optimized treatment strategy for depressive disorder. Adv Exp Med Biol  2019; 1180: 201-17.
 [http://dx.doi.org/10.1007/978-981-32-9271-0_11] [PMID: 31784965]

[8]
Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and management of dementia: Review. JAMA  2019; 322(16): 1589-99.
 [http://dx.doi.org/10.1001/jama.2019.4782] [PMID: 31638686]

[9]
Russo EB, Marcu J. Cannabis pharmacology: The usual suspects and a few promising leads. Adv Pharmacol  2017; 80: 67-134.
 [http://dx.doi.org/10.1016/bs.apha.2017.03.004] [PMID: 28826544]

[10]
Freeman AM, Petrilli K, Lees R, et al. How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review. Neurosci Biobehav Rev  2019; 107: 696-712.
 [http://dx.doi.org/10.1016/j.neubiorev.2019.09.036] [PMID: 31580839]

[11]
Di Marzo V, Piscitelli F. The endocannabinoid system and its modulation by phytocannabinoids. Neurother  2015; 12(4): 692-8.
 [http://dx.doi.org/10.1007/s13311-015-0374-6] [PMID: 26271952]

[12]
Murillo-Rodríguez E, Budde H, Veras AB, et al. The endocannabinoid system may modulate sleep disorders in aging. Curr Neuropharmacol  2020; 18(2): 97-108.
 [http://dx.doi.org/10.2174/1570159X17666190801155922] [PMID: 31368874]

[13]
Petrunich-Rutherford ML, Calik MW. Effects of cannabinoid agonists and antagonists on sleep in laboratory animals. Adv Exp Med Biol  2021; 1297: 97-109.
 [http://dx.doi.org/10.1007/978-3-030-61663-2_7] [PMID: 33537939]

[14]
Kesner AJ, Lovinger DM. Cannabinoids, endocannabinoids and sleep. Front Mol Neurosci  2020; 13: 125.
 [http://dx.doi.org/10.3389/fnmol.2020.00125] [PMID: 32774241]

[15]
Lutz B. Neurobiology of cannabinoid receptor signaling Dialogues Clin Neurosci  2020; 22(3): 207-22.
 [http://dx.doi.org/10.31887/DCNS.2020.22.3/blutz] [PMID: 33162764]

[16]
Shahbazi F, Grandi V, Banerjee A, Trant JF. Cannabinoids and cannabinoid receptors: The story so far. iScience  2020; 23(7): 101301.
 [http://dx.doi.org/10.1016/j.isci.2020.101301] [PMID: 32629422]

[17]
Biernacki M, Skrzydlewska E. Metabolism of endocannabinoids. Postepy Hig Med Dosw  2016; 70: 830-43.
 [http://dx.doi.org/10.5604/17322693.1213898] [PMID: 27516570]

[18]
Tsuboi K, Uyama T, Okamoto Y, Ueda N. Endocannabinoids and related N-acylethanolamines: Biological activities and metabolism. Inflamm Regen  2018; 38(1): 28.
 [http://dx.doi.org/10.1186/s41232-018-0086-5] [PMID: 30288203]

[19]
Freitas HR, Isaac AR, Malcher-Lopes R, Diaz BL, Trevenzoli IH, De Melo Reis RA. Polyunsaturated fatty acids and endocannabinoids in health and disease. Nutr Neurosci  2018; 21(10): 695-714.
 [http://dx.doi.org/10.1080/1028415X.2017.1347373] [PMID: 28686542]

[20]
Gil-Ordóñez A, Martín-Fontecha M, Ortega-Gutiérrez S, López-Rodríguez ML. Monoacylglycerol lipase (MAGL) as a promising therapeutic target. Biochem Pharmacol  2018; 157: 18-32.
 [http://dx.doi.org/10.1016/j.bcp.2018.07.036] [PMID: 30059673]

[21]
Toczek M, Malinowska B. Enhanced endocannabinoid tone as a potential target of pharmacotherapy. Life Sci  2018; 204: 20-45.
 [http://dx.doi.org/10.1016/j.lfs.2018.04.054] [PMID: 29729263]

[22]
Fagundo AB, de la Torre R, Jiménez-Murcia S, et al. Modulation of the endocannabinoids N-arachidonoylethanolamine (aea) and 2-arachidonoylglycerol (2-ag) on executive functions in humans. PLoS One  2013; 8(6): e66387.
 [http://dx.doi.org/10.1371/journal.pone.0066387] [PMID: 23840456]

[23]
Hu SS, Mackie K. Distribution of the endocannabinoid system in the central nervous system. Handb Exp Pharmacol  2015; 231: 59-93.
 [http://dx.doi.org/10.1007/978-3-319-20825-1_3] [PMID: 26408158]

[24]
Hillard CJ. The endocannabinoid signaling system in the CNS: A primer. Int Rev Neurobiol  2015; 125: 1-47.
 [http://dx.doi.org/10.1016/bs.irn.2015.10.001] [PMID: 26638763]

[25]
Bisogno T, Berrendero F, Ambrosino G, et al. Brain regional distribution of endocannabinoids: Implications for their biosynthesis and biological function. Biochem Biophys Res Commun  1999; 256(2): 377-80.
 [http://dx.doi.org/10.1006/bbrc.1999.0254] [PMID: 10079192]

[26]
Kendall DA, Yudowski GA. Cannabinoid receptors in the central nervous system: Their signaling and roles in disease. Front Cell Neurosci  2017; 10: 294.
 [http://dx.doi.org/10.3389/fncel.2016.00294] [PMID: 28101004]

[27]
Shenglong Z, Kumar U. Cannabinoid receptors and the endocannabinoid system: Signaling and function in the central nervous system. Int J Mol Sci  2018; 19(3): 833.
 [http://dx.doi.org/10.3390/ijms19030833]

[28]
Biegon A, Kerman IA. Autoradiographic study of pre- and postnatal distribution of cannabinoid receptors in human brain. Neuroimage  2001; 14(6): 1463-8.
 [http://dx.doi.org/10.1006/nimg.2001.0939] [PMID: 11707102]

[29]
Rusjan PM, Wilson AA, Mizrahi R, et al. Mapping human brain fatty acid amide hydrolase activity with PET. J Cereb Blood Flow Metab  2013; 33(3): 407-14.
 [http://dx.doi.org/10.1038/jcbfm.2012.180] [PMID: 23211960]

[30]
Clapper JR, Henry CL, Niphakis MJ, et al. Monoacylglycerol lipase inhibition in human and rodent systems supports clinical evaluation of endocannabinoid modulators. J Pharmacol Exp Ther  2018; 367(3): 494-508.
 [http://dx.doi.org/10.1124/jpet.118.252296] [PMID: 30305428]

[31]
Vecchini Rodríguez CM, Escalona Meléndez Y, Flores-Otero J. Cannabinoid receptors and ligands: Lessons from CNS disorders and the quest for novel treatment venues. Adv Exp Med Biol  2021; 1297: 43-64.
 [http://dx.doi.org/10.1007/978-3-030-61663-2_4] [PMID: 33537936]

[32]
Redlich C, Dlugos A, Hill MN, et al. The endocannabinoid system in humans: Significant associations between anandamide, brain function during reward feedback and a personality measure of] reward dependence. Neuropsychopharmacology  2021; 46(5): 1020-7.
 [http://dx.doi.org/10.1038/s41386-020-00870-x] [PMID: 33007775]

[33]
Bobrich M, Schwarz R, Ramer R, Borchert P, Hinz B. A simple LC-MS/MS method for the simultaneous quantification of endocannabinoids in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci  2020; 1161: 122371.
 [http://dx.doi.org/10.1016/j.jchromb.2020.122371] [PMID: 33246277]

[34]
Garani R, Watts JJ, Mizrahi R. Endocannabinoid system in psychotic and mood disorders, a review of human studies. Prog Neuropsychopharmacol Biol Psychiatry  2021; 106: 110096.
 [http://dx.doi.org/10.1016/j.pnpbp.2020.110096] [PMID: 32898588]

[35]
Navarrete F, García-Gutiérrez MS, Jurado-Barba R, et al. Endocannabinoid system components as potential biomarkers in psychiatry. Front Psychiatry  2020; 11: 315.
 [http://dx.doi.org/10.3389/fpsyt.2020.00315] [PMID: 32395111]

[36]
Bortolato M, Campolongo P, Mangieri RA, et al. Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology  2006; 31(12): 2652-9.
 [http://dx.doi.org/10.1038/sj.npp.1301061] [PMID: 16541083]

[37]
Wang Y, Gu N, Duan T, et al. Monoacylglycerol lipase inhibitors produce pro- or antidepressant responses via hippocampal CA1 GABAergic synapses. Mol Psychiatry  2017; 22(2): 215-26.
 [http://dx.doi.org/10.1038/mp.2016.22] [PMID: 27001616]

[38]
Kolla NJ, Mizrahi R, Karas K, et al. Elevated fatty acid amide hydrolase in the prefrontal cortex of borderline personality disorder: A [11C]CURB positron emission tomography study. Neuropsychopharmacology  2020; 45(11): 1834-41.
 [http://dx.doi.org/10.1038/s41386-020-0731-y] [PMID: 32521537]

[39]
Schmidt ME, Liebowitz MR, Stein MB, et al. The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: A double-blind, randomized, placebo-controlled proof-of-concept study. Neuropsychopharmacology 2020.
 [http://dx.doi.org/10.1038/s41386-020-00888-1] [PMID: 33070154]

[40]
Joshi N, Onaivi ES. Psychiatric disorders and cannabinoid receptors. Adv Exp Med Biol  2021; 1264: 131-53.
 [http://dx.doi.org/10.1007/978-3-030-57369-0_9] [PMID: 33332008]

[41]
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: Am. Psychiatr Publ. 2013. Available from: https://www.psychiatry.org/psychiatrists/practice/dsm

[42]
International classification of diseases 11th revision. World health organization.  https://icd.who.int/en

[43]
Kessler RC, Demler O, Frank RG, et al. Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med  2005; 352(24): 2515-23.
 [http://dx.doi.org/10.1056/NEJMsa043266] [PMID: 15958807]

[44]
Krueger RF. The structure of common mental disorders. Arch Gen Psychiatry  1999; 56(10): 921-6.
 [http://dx.doi.org/10.1001/archpsyc.56.10.921] [PMID: 10530634]

[45]
Rehm J, Shield KD. Global burden of disease and the impact of mental and addictive disorders. Curr Psychiatry Rep  2019; 21(2): 10.
 [http://dx.doi.org/10.1007/s11920-019-0997-0] [PMID: 30729322]

[46]
Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: Findings from the Global Burden of Disease Study 2010. Lancet  2013; 382(9904): 1575-86.
 [http://dx.doi.org/10.1016/S0140-6736(13)61611-6] [PMID: 23993280]

[47]
Publishing O. OECD glossary of statistical terms Paris OECD Obs 2008. Available from:https://www.oecd-ilibrary.org/economics/oecd-glossary-of-statistical-terms_9789264055087-en
 [http://dx.doi.org/10.1787/9789264055087-en]

[48]
Lajoie J. Understanding the measurement of global burden of disease/. Winnipeg, Manitoba: National Collaborating Centre for Infectious Diseases 2015. Available from: https://nccid.ca/publications/understanding-the-measurement-of-global-burden-ofdisease

[49]
Trautmann S, Rehm J, Wittchen HU. The economic costs of mental disorders: Do our societies react appropriately to the burden of mental disorders? EMBO Rep  2016; 17(9): 1245-9.
 [http://dx.doi.org/10.15252/embr.201642951] [PMID: 27491723]

[50]
Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol  2011; 21(9): 655-79.
 [http://dx.doi.org/10.1016/j.euroneuro.2011.07.018] [PMID: 21896369]

[51]
Andrews G, Sanderson K, Slade T, Issakidis C. Why does the burden of disease persist? Relating the burden of anxiety and depression to effectiveness of treatment. Bull World Health Organ  2000; 78(4): 446-54.
 [PMID: 10885163]

[52]
Gorman JM. Comorbid depression and anxiety spectrum disorders. Depress Anxiety  1996-1997; 4(4): 160-8.
 [http://dx.doi.org/10.1002/(SICI)1520-6394(1996)4:4<160::AID-DA2>3.0.CO;2-J] [PMID: 9166648]

[53]
Saha S, Lim CCW, Cannon DL, et al. Co-morbidity between mood and anxiety disorders: A systematic review and meta-analysis. Depress Anxiety  2021; 38(3): 286-306.
 [http://dx.doi.org/10.1002/da.23113] [PMID: 33225514]

[54]
Bernstein GA. Comorbidity and severity of anxiety and depressive disorders in a clinic sample. J Am Acad Child Adolesc Psychiatry  1991; 30(1): 43-50.
 [http://dx.doi.org/10.1097/00004583-199101000-00007] [PMID: 2005063]

[55]
Lewinsohn PM, Gotlib IH, Seeley JR. Adolescent psychopathology: IV. Specificity of psychosocial risk factors for depression and substance abuse in older adolescents. J Am Acad Child Adolesc Psychiatry  1995; 34(9): 1221-9.
 [http://dx.doi.org/10.1097/00004583-199509000-00021] [PMID: 7559318]

[56]
Lewinsohn PM, Rohde P, Seeley JR. The Clinical Consequences of Comorbidity. Adolescent psychopathology: III. The clinical consequences of comorbidity. J Am Acad Child Adolesc Psychiatry  1995; 34(4): 510-9.
 [http://dx.doi.org/10.1097/00004583-199504000-00018] [PMID: 7751265]

[57]
Rubino T, Zamberletti E, Parolaro D. Endocannabinoids and mental disorders. Handb Exp Pharmacol  2015; 231: 261-83.
 [http://dx.doi.org/10.1007/978-3-319-20825-1_9] [PMID: 26408164]

[58]
Aran A, Eylon M, Harel M, et al. Lower circulating endocannabinoid levels in children with autism spectrum disorder. Mol Autism  2019; 10(1): 2.
 [http://dx.doi.org/10.1186/s13229-019-0256-6] [PMID: 30728928]

[59]
Romero-Sanchiz P, Nogueira-Arjona R, Pastor A, et al. Plasma concentrations of oleoylethanolamide in a primary care sample of depressed patients are increased in those treated with selective serotonin reuptake inhibitor-type antidepressants. Neuropharmacology  2019; 149: 212-20.
 [http://dx.doi.org/10.1016/j.neuropharm.2019.02.026] [PMID: 30822499]

[60]
Borgan F, Kokkinou M, Howes O. The cannabinoid CB1 receptor in schizophrenia. Biol Psychiatry Cogn Neurosci Neuroimaging  2020; S2451-9022(20): 30173-7.
 [http://dx.doi.org/10.1016/j.bpsc.2020.06.018]

[61]
Arjmand S, Behzadi M, Kohlmeier KA, Mazhari S, Sabahi A, Shabani M. Bipolar disorder and the endocannabinoid system. Acta Neuropsychiatr  2019; 31(4): 193-201.
 [http://dx.doi.org/10.1017/neu.2019.21] [PMID: 31159897]

[62]
Chadwick VL, Rohleder C, Koethe D, Leweke FM. Cannabinoids and the endocannabinoid system in anxiety, depression, and dysregulation of emotion in humans. Curr Opin Psychiatry  2020; 33(1): 20-42.
 [http://dx.doi.org/10.1097/YCO.0000000000000562] [PMID: 31714262]

[63]
Kruk-Slomka M, Michalak A, Biala G. Antidepressant-like effects of the cannabinoid receptor ligands in the forced swimming test in mice: Mechanism of action and possible interactions with cholinergic system. Behav Brain Res  2015; 284: 24-36.
 [http://dx.doi.org/10.1016/j.bbr.2015.01.051] [PMID: 25660201]

[64]
Penn A. Cannabinoids and mental health, part 1: The endocannabinoid system and exogenous cannabinoids. J Psychosoc Nurs Ment Health Serv  2019; 57(9): 7-10.
 [http://dx.doi.org/10.3928/02793695-20190813-01] [PMID: 31461513]

[65]
Wośko S, Serefko A, Szopa A, et al. CB1 cannabinoid receptor ligands augment the antidepressant-like activity of biometals (magnesium and zinc) in the behavioural tests. J Pharm Pharmacol  2018; 70(4): 566-75.
 [http://dx.doi.org/10.1111/jphp.12880] [PMID: 29380383]

[66]
Aso E, Ozaita A, Serra MÀ, Maldonado R. Genes differentially expressed in CB1 knockout mice: Involvement in the depressive-like phenotype. Eur Neuropsychopharmacol  2011; 21(1): 11-22.
 [http://dx.doi.org/10.1016/j.euroneuro.2010.06.007] [PMID: 20692131]

[67]
Valverde O, Torrens M. CB1 receptor-deficient mice as a model for depression. Neuroscience  2012; 204: 193-206.
 [http://dx.doi.org/10.1016/j.neuroscience.2011.09.031] [PMID: 21964469]

[68]
Moreira FA, Grieb M, Lutz B. Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: Focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab  2009; 23(1): 133-44.
 [http://dx.doi.org/10.1016/j.beem.2008.09.003] [PMID: 19285266]

[69]
Beyer CE, Dwyer JM, Piesla MJ, et al. Depression-like phenotype following chronic CB1 receptor antagonism. Neurobiol Dis  2010; 39(2): 148-55.
 [http://dx.doi.org/10.1016/j.nbd.2010.03.020] [PMID: 20381618]

[70]
Hill MN, Miller GE, Ho WS, Gorzalka BB, Hillard CJ. Serum endocannabinoid content is altered in females with depressive disorders: A preliminary report. Pharmacopsychiatry  2008; 41(2): 48-53.
 [http://dx.doi.org/10.1055/s-2007-993211] [PMID: 18311684]

[71]
Hill MN, Miller GE, Carrier EJ, Gorzalka BB, Hillard CJ. Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology  2009; 34(8): 1257-62.
 [http://dx.doi.org/10.1016/j.psyneuen.2009.03.013] [PMID: 19394765]

[72]
Pertwee RG. Targeting the endocannabinoid system with cannabinoid receptor agonists: Pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci  2012; 367(1607): 3353-63.
 [http://dx.doi.org/10.1098/rstb.2011.0381] [PMID: 23108552]

[73]
Coccaro EF, Hill MN, Robinson L, Lee RJ. Circulating endocannabinoids and affect regulation in human subjects. Psychoneuroendocrinology  2018; 92: 66-71.
 [http://dx.doi.org/10.1016/j.psyneuen.2018.03.009] [PMID: 29627714]

[74]
Lowe H, Toyang N, Steele B, Bryant J, Ngwa W. The endocannabinoid system: A potential target for the treatment of various diseases. Int J Mol Sci  2021; 22(17): 9472.
 [http://dx.doi.org/10.3390/ijms22179472] [PMID: 34502379]

[75]
Cristino L, Bisogno T, Di Marzo V. Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat Rev Neurol  2020; 16(1): 9-29.
 [http://dx.doi.org/10.1038/s41582-019-0284-z] [PMID: 31831863]

[76]
Bedse G, Hill MN, Patel S. 2-Arachidonoylglycerol modulation of anxiety and stress adaptation: From grass roots to novel therapeutics. Biol Psychiatry  2020; 88(7): 520-30.
 [http://dx.doi.org/10.1016/j.biopsych.2020.01.015] [PMID: 32197779]

[77]
Jenniches I, Ternes S, Albayram O, et al. Anxiety, stress, and fear response in mice with reduced endocannabinoid levels. Biol Psychiatry  2016; 79(10): 858-68.
 [http://dx.doi.org/10.1016/j.biopsych.2015.03.033] [PMID: 25981172]

[78]
Smaga I, Jastrzębska J, Zaniewska M, et al. Changes in the brain endocannabinoid system in rat models of depression. Neurotox Res  2017; 31(3): 421-35.
 [http://dx.doi.org/10.1007/s12640-017-9708-y] [PMID: 28247204]

[79]
Silveira KM, Wegener G, Joca SRL. Targeting 2-arachidonoylglycerol signalling in the neurobiology and treatment of depression. Basic Clin Pharmacol Toxicol  2021; 129(1): 3-14.
 [http://dx.doi.org/10.1111/bcpt.13595] [PMID: 33905617]

[80]
Bouter Y, Brzózka MM, Rygula R, et al. Chronic psychosocial stress causes increased anxiety-like behavior and alters endocannabinoid levels in the brain of C57Bl/6J mice. Cannabis Cannabinoid Res  2020; 5(1): 51-61.
 [http://dx.doi.org/10.1089/can.2019.0041] [PMID: 32322676]

[81]
Witkin JM, Tzavara ET, Davis RJ, Li X, Nomikos GG. A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders. Trends Pharmacol Sci  2005; 26(12): 609-17.
 [http://dx.doi.org/10.1016/j.tips.2005.10.006] [PMID: 16260047]

[82]
Rana T, Behl T, Sehgal A, et al. Integrating endocannabinoid signalling in depression. J Mol Neurosci  2021; 71(10): 2022-34.
 [http://dx.doi.org/10.1007/s12031-020-01774-7] [PMID: 33471311]

[83]
Ganon-Elazar E, Akirav I. Cannabinoid receptor activation in the basolateral amygdala blocks the effects of stress on the conditioning and extinction of inhibitory avoidance. J Neurosci  2009; 29(36): 11078-88.
 [http://dx.doi.org/10.1523/JNEUROSCI.1223-09.2009] [PMID: 19741114]

[84]
Shoshan N, Segev A, Abush H, Mizrachi Zer-Aviv T, Akirav I. Cannabinoids prevent the differential long-term effects of exposure to severe stress on hippocampal- and amygdala-dependent memory and plasticity. Hippocampus  2017; 27(10): 1093-109.
 [http://dx.doi.org/10.1002/hipo.22755] [PMID: 28667676]

[85]
Robledo P, Martín-García E, Aso E, Maldonado R. Genetically modified mice as tools to understand the neurobiological substrates of depression. Curr Pharm Des  2014; 20(23): 3718-37.
 [http://dx.doi.org/10.2174/13816128113196660741] [PMID: 24180392]

[86]
Soriano D, Brusco A, Caltana L. Further evidence of anxiety- and depression-like behavior for total genetic ablation of cannabinoid receptor type 1. Behav Brain Res  2021; 400: 113007.

[87]
Eggan SM, Stoyak SR, Verrico CD, Lewis DA. Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: Comparison of schizophrenia and major depressive disorder. Neuropsychopharmacology  2010; 35(10): 2060-71.
 [http://dx.doi.org/10.1038/npp.2010.75] [PMID: 20555313]

[88]
Salort G, Hernández-Hernández E, García-Fuster MJ, García-Sevilla JA. Regulation of cannabinoid CB1 and CB2 receptors, neuroprotective mTOR and pro-apoptotic JNK1/2 kinases in postmortem prefrontal cortex of subjects with major depressive disorder. J Affect Disord  2020; 276: 626-35.
 [http://dx.doi.org/10.1016/j.jad.2020.07.074] [PMID: 32871695]

[89]
Neumeister A, Normandin MD, Pietrzak RH, et al. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: A positron emission tomography study. Mol Psychiatry  2013; 18(9): 1034-40.
 [http://dx.doi.org/10.1038/mp.2013.61] [PMID: 23670490]

[90]
Ranganathan M, D’Souza DC. Alterations in the endocannabinoid system in schizophrenia. Biol Psychiatry  2020; 88(9): 675-7.
 [http://dx.doi.org/10.1016/j.biopsych.2020.08.019] [PMID: 33032694]

[91]
Sloan ME, Grant CW, Gowin JL, Ramchandani VA, Le Foll B. Endocannabinoid signaling in psychiatric disorders: A review of positron emission tomography studies. Acta Pharmacol  2019; 40(3): 342-50.
 [http://dx.doi.org/10.1038/s41401-018-0081-z] [PMID: 30166624]

[92]
Varlow C, Boileau I, Wey HY, Liang SH, Vasdev N. Classics in neuroimaging: Imaging the endocannabinoid pathway with PET. ACS Chem Neurosci  2020; 11(13): 1855-62.
 [http://dx.doi.org/10.1021/acschemneuro.0c00305] [PMID: 32559067]

[93]
Ye L, Cao Z, Wang W, Zhou N. New insights in cannabinoid receptor structure and signaling. Curr Mol Pharmacol  2019; 12(3): 239-48.
 [http://dx.doi.org/10.2174/1874467212666190215112036] [PMID: 30767756]

[94]
Koethe D, Pahlisch F, Hellmich M, et al. Familial abnormalities of endocannabinoid signaling in schizophrenia. World J Biol Psychiatry  2019; 20(2): 117-25.
 [http://dx.doi.org/10.1080/15622975.2018.1449966] [PMID: 29521179]

[95]
Rodríguez-Muñoz M, Sánchez-Blázquez P, Callado LF, Meana JJ, Garzón-Niño J. Schizophrenia and depression, two poles of endocannabinoid system deregulation. Transl Psychiatry  2017; 7(12): 1291.
 [http://dx.doi.org/10.1038/s41398-017-0029-y] [PMID: 29249810]

[96]
Ibarra-Lecue I, Pilar-Cuéllar F, Muguruza C, et al. The endocannabinoid system in mental disorders: Evidence from human brain studies. Biochem Pharmacol  2018; 157: 97-107.
 [http://dx.doi.org/10.1016/j.bcp.2018.07.009] [PMID: 30026022]

[97]
Vinod KY, Xie S, Psychoyos D, Hungund BL, Cooper TB, Tejani-Butt SM. Dysfunction in fatty acid amide hydrolase is associated with depressive-like behavior in Wistar Kyoto rats. PLoS One  2012; 7(5): e36743.
 [http://dx.doi.org/10.1371/journal.pone.0036743] [PMID: 22606285]

[98]
Harfmann EJ, McAuliffe TL, Larson ER, et al. Circulating endocannabinoid concentrations in grieving adults. Psychoneuroendocrinology  2020; 120: 104801.
 [http://dx.doi.org/10.1016/j.psyneuen.2020.104801] [PMID: 32682172]

[99]
Bambico FR, Cassano T, Dominguez-Lopez S, et al. Genetic deletion of fatty acid amide hydrolase alters emotional behavior and serotonergic transmission in the dorsal raphe, prefrontal cortex, and hippocampus. Neuropsychopharmacology  2010; 35(10): 2083-100.
 [http://dx.doi.org/10.1038/npp.2010.80] [PMID: 20571484]

[100]
Rafiei D, Kolla NJ. Elevated brain fatty acid amide hydrolase induces depressive-like phenotypes in rodent models: A review. Int J Mol Sci  2021; 22(3): 1047.
 [http://dx.doi.org/10.3390/ijms22031047] [PMID: 33494322]

[101]
Naidu PS, Varvel SA, Ahn K, Cravatt BF, Martin BR, Lichtman AH. Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology (Berl)  2007; 192(1): 61-70.
 [http://dx.doi.org/10.1007/s00213-006-0689-4] [PMID: 17279376]

[102]
Ferber SG, Roth TL, Weller A. Epigenetic fragility of the endocannabinoid system under stress: Risk for mood disorders and pharmacogenomic implications. Epigenomics  2020; 12(8): 657-60.
 [http://dx.doi.org/10.2217/epi-2020-0037] [PMID: 32396405]

[103]
Monteleone P, Bifulco M, Maina G, et al. Investigation of CNR1 and FAAH endocannabinoid gene polymorphisms in bipolar disorder and major depression. Pharmacol Res  2010; 61(5): 400-4.
 [http://dx.doi.org/10.1016/j.phrs.2010.01.002] [PMID: 20080186]

[104]
Lazary J, Eszlari N, Juhasz G, Bagdy G. Genetically reduced FAAH activity may be a risk for the development of anxiety and depression in persons with repetitive childhood trauma. Eur Neuropsychopharmacol  2016; 26(6): 1020-8.
 [http://dx.doi.org/10.1016/j.euroneuro.2016.03.003] [PMID: 27005594]

[105]
Maldonado R, Cabañero D, Martín-García E. The endocannabinoid system in modulating fear, anxiety, and stress Dialogues Clin Neurosci  2020; 22(3): 229-39.
 [http://dx.doi.org/10.31887/DCNS.2020.22.3/rmaldonado] [PMID: 33162766]

[106]
Patel S, Hill MN, Cheer JF, Wotjak CT, Holmes A. The endocannabinoid system as a target for novel anxiolytic drugs. Neurosci Biobehav Rev  2017; 76(Pt A): 56-66.
 [http://dx.doi.org/10.1016/j.neubiorev.2016.12.033] [PMID: 28434588]

[107]
Bedse G, Bluett RJ, Patrick TA, et al. Therapeutic endocannabinoid augmentation for mood and anxiety disorders: Comparative profiling of FAAH, MAGL and dual inhibitors. Transl Psychiatry  2018; 8(1): 92-14.
 [http://dx.doi.org/10.1038/s41398-018-0141-7] [PMID: 29695817]

[108]
Hou L, Rong J, Haider A, et al. Positron emission tomography imaging of the endocannabinoid system: Opportunities and challenges in radiotracer development. J Med Chem  2021; 64(1): 123-49.
 [http://dx.doi.org/10.1021/acs.jmedchem.0c01459] [PMID: 33379862]

[109]
Bersani G, Pacitti F, Iannitelli A, et al. Inverse correlation between plasma 2-arachidonoylglycerol levels and subjective severity of depression. Hum Psychopharmacol  2021; 36(4): e2779.
 [http://dx.doi.org/10.1002/hup.2779] [PMID: 33559925]

[110]
Domschke K, Dannlowski U, Ohrmann P, et al. Cannabinoid receptor 1 (CNR1) gene: Impact on antidepressant treatment response and emotion processing in major depression. Eur Neuropsychopharmacol  2008; 18(10): 751-9.
 [http://dx.doi.org/10.1016/j.euroneuro.2008.05.003] [PMID: 18579347]

[111]
Neumeister A. The endocannabinoid system provides an avenue for evidence-based treatment development for PTSD. Depress Anxiety  2013; 30(2): 93-6.
 [http://dx.doi.org/10.1002/da.22031] [PMID: 23225490]

[112]
Tan H, Lauzon NM, Bishop SF, Bechard MA, Laviolette SR. Integrated cannabinoid CB1 receptor transmission within the amygdala-prefrontal cortical pathway modulates neuronal plasticity and emotional memory encoding. Cereb Cortex  2010; 20(6): 1486-96.
 [http://dx.doi.org/10.1093/cercor/bhp210] [PMID: 19880592]

[113]
Ramikie TS, Patel S. Endocannabinoid signaling in the amygdala: Anatomy, synaptic signaling, behavior, and adaptations to stress. Neuroscience  2012; 204: 38-52.
 [http://dx.doi.org/10.1016/j.neuroscience.2011.08.037] [PMID: 21884761]

[114]
Kuhnert S, Meyer C, Koch M. Involvement of cannabinoid receptors in the amygdala and prefrontal cortex of rats in fear learning, consolidation, retrieval and extinction. Behav Brain Res  2013; 250: 274-84.
 [http://dx.doi.org/10.1016/j.bbr.2013.05.002] [PMID: 23702112]

[115]
Bossong MG, van Hell HH, Jager G, Kahn RS, Ramsey NF, Jansma JM. The endocannabinoid system and emotional processing: A pharmacological fMRI study with Δ9-tetrahydrocannabinol. Eur Neuropsychopharmacol  2013; 23(12): 1687-97.
 [http://dx.doi.org/10.1016/j.euroneuro.2013.06.009] [PMID: 23928295]

[116]
Gorka SM, Fitzgerald DA, de Wit H, Phan KL. Cannabinoid modulation of amygdala subregion functional connectivity to social signals of threat. Int J Neuropsychopharmacol  2014; 18(3): pyu104.
 [http://dx.doi.org/10.1093/ijnp/pyu104] [PMID: 25548107]

[117]
Ceccarini J, Kuepper R, Kemels D, van Os J, Henquet C, Van Laere K. [18F]MK-9470 PET measurement of cannabinoid CB1 receptor availability in chronic cannabis users. Addict Biol  2015; 20(2): 357-67.
 [http://dx.doi.org/10.1111/adb.12116] [PMID: 24373053]

[118]
Weinstein A, Livny A, Weizman A. Brain imaging studies on the cognitive, pharmacological and neurobiological effects of cannabis in humans: Evidence from studies of adult users. Curr Pharm Des  2016; 22(42): 6366-79.
 [http://dx.doi.org/10.2174/1381612822666160822151323] [PMID: 27549374]

[119]
Bhattacharyya S, Egerton A, Kim E, et al. Acute induction of anxiety in humans by delta-9-tetrahydrocannabinol related to amygdalar cannabinoid-1 (CB1) receptors. Sci Rep  2017; 7(1): 15025.
 [http://dx.doi.org/10.1038/s41598-017-14203-4] [PMID: 29101333]

[120]
Ren SY, Wang ZZ, Zhang Y, Chen NH. Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases-focusing on FAAH/MAGL inhibitors. Acta Pharmacol Sin  2020; 41(10): 1263-71.
 [http://dx.doi.org/10.1038/s41401-020-0385-7] [PMID: 32203086]

[121]
Alteba S, Mizrachi Zer-Aviv T, Tenenhaus A, et al. Antidepressant-like effects of URB597 and JZL184 in male and female rats exposed to early life stress. Eur Neuropsychopharmacol  2020; 39: 70-86.
 [http://dx.doi.org/10.1016/j.euroneuro.2020.08.005] [PMID: 32891517]

[122]
Dong B, Shilpa BM, Shah R, et al. Dual pharmacological inhibitor of endocannabinoid degrading enzymes reduces depressive-like behavior in female rats. J Psychiatr Res  2020; 120: 103-12.
 [http://dx.doi.org/10.1016/j.jpsychires.2019.10.010] [PMID: 31654971]

[123]
Pavón FJ, Polis IY, Stouffer DG, et al. Selective inhibition of monoacylglycerol lipase is associated with passive coping behavior and attenuation of stress-induced dopamine release in the medial prefrontal cortex. Neurobiol Stress  2021; 14: 100293.
 [http://dx.doi.org/10.1016/j.ynstr.2021.100293] [PMID: 33490317]

[124]
Paulus MP, Stein MB, Simmons AN, Risbrough VB, Halter R, Chaplan SR. The effects of FAAH inhibition on the neural basis of anxiety-related processing in healthy male subjects: A randomized clinical trial. Neuropsychopharmacology  2021; 46(5): 1011-9.
 [http://dx.doi.org/10.1038/s41386-020-00936-w] [PMID: 33335310]

[125]
Gärtner A, Dörfel D, Diers K, et al. Impact of FAAH genetic variation on fronto-amygdala function during emotional processing. Eur Arch Psychiatry Clin Neurosci  2019; 269(2): 209-21.
 [http://dx.doi.org/10.1007/s00406-018-0944-9] [PMID: 30291441]

[126]
Mayo LM, Asratian A, Lindé J, et al. Elevated anandamide, enhanced recall of fear extinction, and attenuated stress responses following inhibition of fatty acid amide hydrolase: A randomized, controlled experimental medicine trial. Biol Psychiatry  2020; 87(6): 538-47.
 [http://dx.doi.org/10.1016/j.biopsych.2019.07.034] [PMID: 31590924]

[127]
Morena M, Aukema RJ, Leitl KD, et al. Upregulation of anandamide hydrolysis in the basolateral complex of amygdala reduces fear memory expression and indices of stress and anxiety. J Neurosci  2019; 39(7): 1275-92.
 [http://dx.doi.org/10.1523/JNEUROSCI.2251-18.2018] [PMID: 30573646]

[128]
Kaczocha M, Glaser ST, Deutsch DG, Lennarz WJ. Identification of intracellular carriers for the endocannabinoid anandamide. Proc Natl Acad Sci USA  2009; 106(15): 6375-80.
 [http://dx.doi.org/10.1073/pnas.0901515106] [PMID: 19307565]

[129]
Khasabova IA, Holman M, Morse T, et al. Increased anandamide uptake by sensory neurons contributes to hyperalgesia in a model of cancer pain. Neurobiol Dis  2013; 58: 19-28.
 [http://dx.doi.org/10.1016/j.nbd.2013.04.018] [PMID: 23644187]

[130]
Adamczyk P, Gołda A, McCreary AC, Filip M, Przegaliński E. Activation of endocannabinoid transmission induces antidepressant-like effects in rats. J Physiol Pharmacol  2008; 59(2): 217-28.
 [PMID: 18622041]

[131]
Deutsch DG. A personal retrospective: Elevating anandamide (AEA) by targeting fatty acid amide hydrolase (FAAH) and the fatty acid binding proteins (FABPs). Front Pharmacol  2016; 7: 370.
 [http://dx.doi.org/10.3389/fphar.2016.00370] [PMID: 27790143]

[132]
Nazıroğlu M, Taner AN, Balbay E, Çiğ B. Inhibitions of anandamide transport and FAAH synthesis decrease apoptosis and oxidative stress through inhibition of TRPV1 channel in an in vitro seizure model. Mol Cell Biochem  2019; 453(1-2): 143-55.
 [http://dx.doi.org/10.1007/s11010-018-3439-0] [PMID: 30159798]

[133]
Wang YT, Liu CH, Zhu HL. Fatty acid binding protein (FABP) inhibitors: A patent review (2012-2015). Expert Opin Ther Pat  2016; 26(7): 767-76.
 [http://dx.doi.org/10.1080/13543776.2016.1182500] [PMID: 27109571]

[134]
Abdul Bari A B, Samuel P J. Road toward universal COVID-19 testing method - A review. J J Immunoassay Immunochem  2021; 42(4): 335-46.
 [http://dx.doi.org/10.1080/15321819.2021.1895214]

[135]
Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. Res Sq 2021.
 [http://dx.doi.org/10.21203/rs.3.rs-266574/v1]

[136]
Krishnan A, Hamilton JP, Alqahtani SA, Woreta TA. COVID-19: An overview and a clinical update. World J Clin Cases  2021; 9(1): 8-23.
 [http://dx.doi.org/10.12998/wjcc.v9.i1.8] [PMID: 33511168]

[137]
Beig Parikhani A, Bazaz M, Bamehr H, et al. The inclusive review on SARS-CoV-2 biology, epidemiology, diagnosis, and potential management options. Curr Microbiol  2021; 78(4): 1099-114.
 [http://dx.doi.org/10.1007/s00284-021-02396-x] [PMID: 33638671]

[138]
Rolla G, Brussino L, Badiu I, Castells MC, Phillips EJ. Maintaining Safety with SARS-CoV-2 Vaccines. N Engl J Med  2021; 384(10): e37.
 [http://dx.doi.org/10.1056/NEJMc2100766] [PMID: 33567189]

[139]
Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol  2021; 21(2): 73-82.
 [http://dx.doi.org/10.1038/s41577-020-00480-0] [PMID: 33340022]

[140]
Remmel A. COVID vaccines and safety: What the research says. Nature  2021; 590(7847): 538-40.
 [http://dx.doi.org/10.1038/d41586-021-00290-x] [PMID: 33597779]

[141]
López-Bueno R, López-Sánchez GF, Casajús JA, Calatayud J, Tully MA, Smith L. Potential health-related behaviors for pre-school and school-aged children during COVID-19 lockdown: A narrative review. Prev Med  2021; 143: 106349.
 [http://dx.doi.org/10.1016/j.ypmed.2020.106349] [PMID: 33271236]

[142]
Joffe AR. COVID-19: Rethinking the lockdown groupthink. Front Public Health  2021; 9: 625778.
 [http://dx.doi.org/10.3389/fpubh.2021.625778] [PMID: 33718322]

[143]
Tsamakis K, Tsiptsios D, Ouranidis A, et al. COVID-19 and its consequences on mental health (Review). Exp Ther Med  2021; 21(3): 244.
 [http://dx.doi.org/10.3892/etm.2021.9675] [PMID: 33603852]

[144]
Imperatori C, Dakanalis A, Farina B, et al. Global storm of stress-related psychopathological symptoms: A brief overview on the usefulness of virtual reality in facing the mental health impact of COVID-19. Cyberpsychol Behav Soc Netw  2020; 23(11): 782-8.
 [http://dx.doi.org/10.1089/cyber.2020.0339] [PMID: 32640852]

[145]
Yamamoto T, Uchiumi C, Suzuki N, Yoshimoto J, Murillo-Rodriguez E. The psychological impact of ‘mild lockdown’ in japan during the covid-19 pandemic: A nationwide survey under a declared state of emergency. Int J Environ Res Public Health  2020; 17(24): 9382.
 [http://dx.doi.org/10.3390/ijerph17249382] [PMID: 33333893]

[146]
Yan T, Zhizhong W, Jianzhong Z, et al. Depressive and anxiety symptoms among people under quarantine during the COVID-19 epidemic in China: A cross-sectional study. Front Psychiatry  2021; 12: 566241.
 [http://dx.doi.org/10.3389/fpsyt.2021.566241] [PMID: 33658949]

[147]
Li X, Lyu H. Epidemic risk perception, perceived stress, and mental health during COVID-19 pandemic: A moderated mediating model. Front Psychol  2021; 11: 563741.
 [http://dx.doi.org/10.3389/fpsyg.2020.563741] [PMID: 33643107]

[148]
Kahlon MK, Aksan N, Aubrey R, et al. Effect of layperson-delivered, empathy-focused program of telephone calls on loneliness, depression, and anxiety among adults during the COVID-19 pandemic: A randomized clinical trial. JAMA Psychiatry  2021; 78(6): 616-22.
 [http://dx.doi.org/10.1001/jamapsychiatry.2021.0113] [PMID: 33620417]

[149]
Gullo S, Misici I, Teti A, Liuzzi M, Chiara E. Going through the lockdown: A longitudinal study on the psychological consequences of the coronavirus pandemic. Res Psychother  2021; 23(3): 494.
 [http://dx.doi.org/10.4081/ripppo.2020.494] [PMID: 33585300]

[150]
Panno A, Carbone GA, Massullo C, Farina B, Imperatori C. COVID-19 related distress is associated with alcohol problems, social media and food addiction symptoms: Insights from the Italian experience during the lockdown. Front Psychiatry  2020; 11: 577135.
 [http://dx.doi.org/10.3389/fpsyt.2020.577135] [PMID: 33324256]

[151]
Gao W, Walther A, Wekenborg M, Penz M, Kirschbaum C. Determination of endocannabinoids and N-acylethanolamines in human hair with LC-MS/MS and their relation to symptoms of depression, burnout, and anxiety. Talanta  2020; 217: 121006.
 [http://dx.doi.org/10.1016/j.talanta.2020.121006] [PMID: 32498885]

[152]
Estrada JA, Contreras I. Endocannabinoid receptors in the CNS: Potential drug targets for the prevention and treatment of neurologic and psychiatric disorders. Curr Neuropharmacol  2020; 18(8): 769-87.
 [http://dx.doi.org/10.2174/1570159X18666200217140255] [PMID: 32065105]

[153]
Dow-Edwards D. Sex differences in the interactive effects of early life stress and the endocannabinoid system. Neurotoxicol Teratol  2020; 80: 106893.
 [http://dx.doi.org/10.1016/j.ntt.2020.106893] [PMID: 32437941]

[154]
Pinna G. Endocannabinoids and precision medicine for mood disorders and suicide. Front Psychiatry  2021; 12: 658433.
 [http://dx.doi.org/10.3389/fpsyt.2021.658433] [PMID: 34093274]

[155]
Lazary J, Eszlari N, Kriko E, et al. Genetic analyses of the endocannabinoid pathway in association with affective phenotypic variants. Neurosci Lett  2021; 744: 135600.
 [http://dx.doi.org/10.1016/j.neulet.2020.135600] [PMID: 33421489]

[156]
Alteba S, Portugalov A, Hillard CJ, Akirav I. Inhibition of Fatty Acid Amide Hydrolase (FAAH) during adolescence and exposure to early life stress may exacerbate depression-like behaviors in male and female rats. Neuroscience  2021; 455: 89-106.
 [http://dx.doi.org/10.1016/j.neuroscience.2020.12.022] [PMID: 33359656]

[157]
Brellenthin AG, Crombie KM, Hillard CJ, Koltyn KF. Endocannabinoid and mood responses to exercise in adults with varying activity levels. Med Sci Sports Exerc  2017; 49(8): 1688-96.
 [http://dx.doi.org/10.1249/MSS.0000000000001276] [PMID: 28319590]

[158]
Meyer JD, Crombie KM, Cook DB, Hillard CJ, Koltyn KF. Serum endocannabinoid and mood changes after exercise in major depressive disorder. Med Sci Sports Exerc  2019; 51(9): 1909-17.
 [http://dx.doi.org/10.1249/MSS.0000000000002006] [PMID: 30973483]

[159]
Amatriain-Fernández S, Budde H, Gronwald T, et al. The endocannabinoid system as modulator of exercise benefits in mental health. Curr Neuropharmacol  2021; 19(8): 1304-22.
 [http://dx.doi.org/10.2174/1570159X19666201218112748] [PMID: 33342414]

[160]
Yarrington JS, Lasser J, Garcia D, et al. Impact of the COVID-19 pandemic on mental health among 157,213 Americans. J Affect Disord  2021; 286: 64-70.
 [http://dx.doi.org/10.1016/j.jad.2021.02.056] [PMID: 33677184]

[161]
Brenner MH, Bhugra D. Acceleration of anxiety, depression, and suicide: Secondary effects of economic disruption related to COVID-19. Front Psychiatry  2020; 11: 592467.
 [http://dx.doi.org/10.3389/fpsyt.2020.592467] [PMID: 33384627]

[162]
Fruehwirth JC, Biswas S, Perreira KM. The Covid-19 pandemic and mental health of first-year college students: Examining the effect of Covid-19 stressors using longitudinal data. PLoS One  2021; 16(3): e0247999.
 [http://dx.doi.org/10.1371/journal.pone.0247999] [PMID: 33667243]

[163]
Moayed MS, Vahedian-Azimi A, Mirmomeni G, et al. Depression, anxiety, and stress among patients with COVID-19: A cross-sectional study. Adv Exp Med Biol  2021; 1321: 229-36.
 [http://dx.doi.org/10.1007/978-3-030-59261-5_19] [PMID: 33656727]

[164]
Kingstone T, Taylor AK, O’Donnell CA, Atherton H, Blane DN, Chew-Graham CA. Finding the ‘right’ GP: A qualitative study of the experiences of people with long-COVID. BJGP Open  2020; 4(5): bjgpopen20X101143.
 [http://dx.doi.org/10.3399/bjgpopen20X101143] [PMID: 33051223]

[165]
Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med  2021; 27(4): 626-31.
 [http://dx.doi.org/10.1038/s41591-021-01292-y] [PMID: 33692530]

[166]
Rubin R. Collecting data about COVID-19-related brain symptoms. JAMA  2021; 325(8): 712.
 [http://dx.doi.org/10.1001/jama.2021.0791] [PMID: 33620387]

[167]
Sher L. Post-COVID syndrome and suicide risk. QJM  2021; 114(2): 95-8.
 [http://dx.doi.org/10.1093/qjmed/hcab007] [PMID: 33486531]

[168]
Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med  2021; 27(4): 601-15.
 [http://dx.doi.org/10.1038/s41591-021-01283-z] [PMID: 33753937]

[169]
Lee CR, Chen A, Tye KM. The neural circuitry of social homeostasis: Consequences of acute versus chronic social isolation. Cell  2021; 184(6): 1500-16.
 [http://dx.doi.org/10.1016/j.cell.2021.02.028] [PMID: 33691140]
Cite As
CNS & Neurological Disorders - Drug Targets

The Endocannabinoid System as a Biomarker for Diagnostic and Therapeutic Applications in Depression and Anxiety

Abstract
